Title |
Recent advances in the molecular understanding of glioblastoma
|
---|---|
Published in |
Journal of Neuro-Oncology, January 2012
|
DOI | 10.1007/s11060-011-0793-0 |
Pubmed ID | |
Authors |
Fonnet E. Bleeker, Remco J. Molenaar, Sieger Leenstra |
Abstract |
Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor's resistance to current therapeutic approaches. Thus far, methylation of the O (6)-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel "genome-wide" techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | <1% |
Brazil | 2 | <1% |
Germany | 1 | <1% |
Finland | 1 | <1% |
United Kingdom | 1 | <1% |
Netherlands | 1 | <1% |
Denmark | 1 | <1% |
Belgium | 1 | <1% |
Spain | 1 | <1% |
Other | 1 | <1% |
Unknown | 550 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 126 | 22% |
Student > Master | 98 | 17% |
Student > Ph. D. Student | 74 | 13% |
Researcher | 54 | 10% |
Student > Doctoral Student | 32 | 6% |
Other | 70 | 12% |
Unknown | 110 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 118 | 21% |
Agricultural and Biological Sciences | 94 | 17% |
Biochemistry, Genetics and Molecular Biology | 88 | 16% |
Neuroscience | 28 | 5% |
Chemistry | 28 | 5% |
Other | 82 | 15% |
Unknown | 126 | 22% |